ERBB2 and neoplasm: Hormone receptor (HR), human epidermal growth factor receptor 2 (HER2), breast cancer 1/2 gene (BRCA 1/2), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, programmed death-ligand 1 status, as well as biological age, tumor burden, and prior therapies critically influence prognosis [2, 3, 4].